Follicle regulatory protein: A novel marker for granulosa cell cancer patients

Rodgers, Kathleen E.; Marks, Jamie F.; Ellefson, Dolph D.; Yanagihara, Donna L.; Tonetta, Sharon A.; Vasilev, Steven A.; Morrow, C. Paul; Montz, F.J.; diZerega, Gere S.

doi:10.1016/0090-8258(90)90372-r

Cited by 14 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated levels of FRP have been detected in some patients with granulosa cell tumors. 50 The clinical importance of this marker is not yet known.…”

Section: Follicle Regulatory Protein (Frp)mentioning

confidence: 99%

“…However, a mixture of these patterns is often found in an individual tumor. 1,10,15,50 Tumors in the moderately differentiated category have a diffuse pattern that has been designated "sarcomatoid." Occasionally, granulosa cell tumors with a diffuse pattern can be mistaken for a poorly differentiated carcinoma on intraoperative frozen section.…”

Section: Pathologymentioning

confidence: 99%

“…2,[10][11][12]14,50 For patients with granulosa cell tumors, the overall 10year survival rates have been reported as being between 60% and 90%, but the 25-year survival rate is only in the range of 40% to 60%. 2,9,15,[50][51][52] The 5-year survival rate for patients with stage I ranges from 90% to 95% (>90% survival rate in the majority of the studies). [1][2][3]12,13,15,50 The 10year survival rate is between 85% and 95%.…”

Section: Prognostic Factorsmentioning

confidence: 99%

“…2,9,15,[50][51][52] The 5-year survival rate for patients with stage I ranges from 90% to 95% (>90% survival rate in the majority of the studies). [1][2][3]12,13,15,50 The 10year survival rate is between 85% and 95%. 10,13,53 Because 60% to 90% of patients present with stage I disease, 1,2,10,13 the definition of pathologic prognostic factors relates principally to stage I tumors.…”

Section: Prognostic Factorsmentioning

confidence: 99%

See 3 more Smart Citations

Granulosa Cell Tumor of the Ovary: Tumor Review

et al. 2008

View full text Add to dashboard Cite

Granulosa cell tumors of the ovary are rare neoplasms that originate from sex-cord stromal cells. The long natural history of granulosa cell tumors and their tendency to recur years after the initial diagnosis are the most prominent of their characteristics. The secretion of estradiol is the reason for signs at presentation such as vaginal bleeding and precocious puberty. Abdominal pain and hemoperitoneum, which occasionally can occur, are attributable to tumor rupture. The most common finding in pelvic examination is a tumor mass, which is subsequently confirmed with imaging techniques. Surgery is the mainstay of initial management for histological diagnosis, appropriate staging, and debulking. A more conservative unilateral salpingo-oophorectomy is indicated in patients with stage I disease and patients of reproductive age. Total abdominal hysterectomy with bilateral salpingo-oophorectomy is the appropriate surgical treatment for postmenopausal women and those with more advanced disease. The stage of disease is the most important prognostic factor associated with the risk of relapse. There are no clear conclusions regarding the role of postoperative chemotherapy or radiotherapy in stage I disease and in those with completely resected tumor. The use of adjuvant chemotherapy or radiotherapy has sometimes been associated with prolonged disease-free survival and possibly overall survival. Chemotherapy is the treatment of choice for patients with advanced, recurrent, or metastatic disease, and BEP (bleomycin, etoposide, and cisplatin) is the preferred regimen. Although the overall rate of response to treatment is high, the impact of treatment on disease-free or overall survival is unknown. Prolonged surveillance is mandatory because tumors tend to recur years after the initial diagnosis.

show abstract

“…Elevated levels of FRP have been detected in some patients with granulosa cell tumors. 50 The clinical importance of this marker is not yet known.…”

Section: Follicle Regulatory Protein (Frp)mentioning

confidence: 99%

Section: Pathologymentioning

confidence: 99%

Section: Prognostic Factorsmentioning

confidence: 99%

Section: Prognostic Factorsmentioning

confidence: 99%

See 2 more Smart Citations

Granulosa Cell Tumor of the Ovary: Tumor Review

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Oestradiol is a less reliable serum marker. Potential markers include follicle-regulatory protein [13]and mullerian inhibitory substance [14, 15]. …”

Section: Granulosa and Theca Cell Tumoursmentioning

confidence: 99%

Management of Non-Epithelial Ovarian Tumours

Bridgewater

Rustin²

1999

Oncology

View full text Add to dashboard Cite

Ovarian tumours of non-epithelial origin are less common than those of epithelial origin but must be distinguished from these as their natural history and management differ. As these tumours are rare, histological review by an expert in the field is essential. There have been no randomised trials to outline the management of these tumours and therefore this paper represents a review of descriptive data. Non-epithelial ovarian tumours, which represent approximately 50% of all ovarian tumours and approximately 25% of malignant ovarian tumours, are outlined. Lymphomas and metastatic tumours should be treated the same as when found in other sites and will not be discussed further.

show abstract

Immunocytochemical localization of follicle regulatory‐protein (FRP) in testis

et al. 1991

Self Cite

View full text Add to dashboard Cite

Follicle regulatory protein (FRP) can exert paracrine control over follicular development. It is synthesized by the granulosa cells of the developing follicles and was localized in the cytoplasm of the mural cells by immunocytochemistry. When administered to male dogs and rats, FRP causes impairment of spermatogenesis. In the intact male rat, it has been postulated that FRP manifests its effects at a stage prior to the conversion of testosterone to dihydrotestosterone. Sertoli cells of the seminiferous tubules are implicated in testosterone metabolism. Furthermore, Sertoli cells in male gonads are regarded as the counterpart of granulosa cells in ovaries. The exact source of FRP in the male is not known. Therefore, it was of interest to study the localization of FRP in the male gonads. Testicular sections of the pig, dog, cat, rat, mouse, monkey, and man were immunocytochemically stained with monoclonal antibody to porcine FRP of ovarian origin. Sections of pig ovaries were used as controls throughout the study. Specificity of immunocytochemical localization was established by preabsorption. FRP antibody predominantly localized to the interstitial compartment of the pig testis. In the seminiferous tubules, FRP localization was limited to basal spermatogonia and Sertoli cells of tubules at few specific stages of spermatogenesis. The study also showed that the monoclonal antibody against porcine FRP is species-specific. Antibody binding was found only in pig testis, whereas tissues from the cat, dog, mouse, rat, monkey, and man did not display any immunocytochemical reaction.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Follicle regulatory protein: A novel marker for granulosa cell cancer patients

Cited by 14 publications

References 15 publications

Granulosa Cell Tumor of the Ovary: Tumor Review

Granulosa Cell Tumor of the Ovary: Tumor Review

Management of Non-Epithelial Ovarian Tumours

Immunocytochemical localization of follicle regulatory‐protein (FRP) in testis

Contact Info

Product

Resources

About